Previous 10 | Next 10 |
home / stock / sgioy / sgioy news
Summary Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside. However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit an...
Shionogi ( OTCPK:SGIOY ) CEO Isao Teshirogi expects that assuming it wins US regulatory approval, the Japanese pharma's COVID-19 pill Xocova (ensitrelvir) will lead to $2B in annual sales. Speaking with Reuters, Teshirogi said that Xocova's US FDA approval could come in the wint...
Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and Accounting Department Ryuichi Kiyama - Senior Executive Officer and Seni...
Shionogi ( OTCPK:SGIOF ) ( OTCPK:SGIOY ) said its oral COVID-19 drug S-217622 helped patients achieve resolution of five Omicron-related symptoms faster, compared to placebo, thereby meeting the main goal of a phase 3 part of a phase 2/3 study conducted i...
Shionogi & Co., Ltd. (SGIOF) Q1 2022 Earnings Conference Call August 1, 2022 01:45 ET Company Participants Yoshimasa Kyokawa - Investor Relations John Keller - Senior Executive Officer and Senior Vice President, R&D Supervisory Unit Toshinobu Iwasaki - Se...
Shionogi & Co. press release ( OTCPK:SGIOF ): Q1 GAAP EPS of ¥115.13. Revenue of ¥71.84B (+4.2% Y/Y). For further details see: Shionogi & Co. GAAP EPS of ¥115.13, revenue of ¥71.84B
A group of health experts in Japanese health ministry delayed emergency approval on Wednesday for the COVID-19 pill developed by Osaka-based drugmaker Shionogi & Co. ( OTCPK:SGIOF ) ( OTCPK:SGIOY ), citing the need to continue discussions on the drug. The delay marks the...
Announcing new Phase 2b results for the company’s experimental COVID-19 therapy, S-217622, Japanese drugmaker Shionogi & Co. (OTCPK:SGIOY) (OTCPK:SGIOF) said that the once-daily oral treatment led to a rapid clearance of the virus in a trial conducted in Asia. The Phase 2b part of ...
Paxlovid, the COVID-19 pill developed by Pfizer (NYSE:PFE), is set to generate $23.6 billion in revenue in 2022 to become one of the fastest-selling treatments of all time, London-based data analytics firm Airfinity Ltd. said Friday, according to Bloomberg. While the consensus ...
Ascletis Pharma (OTCPK:ASCLF) said data from antiviral cellular assays suggested that its drug ASC11 showed potential to be effective treatment for COVID-19. The Chinese company said that in antiviral cellular assays, antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a comp...
News, Short Squeeze, Breakout and More Instantly...
Shionogi & Co. Ltd. ADR Company Name:
SGIOY Stock Symbol:
OTCMKTS Market:
Shionogi & Co. Ltd. ADR Website:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
G6 Materials Corp. (GPHBF) is expected to report for quarter end 2023-11-30 High Tide Inc. (HITI) is expected to report $-0.03 for Q4 2023 ServisFirst Bancshares Inc. (SFBS) is expected to report $0.87 for Q4 2023 Sanmina Corporation (SANM) is expected to report $1.05 for Q1 2024 ...